21 papers in the library · 508 citations · publishing 2010-2026
Neurology June 9, 2026 Emmanuelle A. D. Schindler, Kevin Lenaburg, Robert Wold
To carry out a survey on N,N-dimethyltryptamine (DMT) use in adults with cluster headache.
Headache: The Journal of Head and Face Pain February 1, 2026 Faraidoon Haghdoost, Dilara Bahceci, Candice Delcourt et al.
This study was undertaken to identify gaps in cluster headache management, highlight patient-prioritized research needs, and assess patient interest in, and preferences for, clinical trial participation. Many people with cluster headache still lack effective treatment options to control or prevent attacks. There is a critical need for more studies, particularly clinical trials, in this field....
Headache: The Journal of Head and Face Pain December 29, 2025 Emmanuelle A. D. Schindler, Christopher Gottschalk, Brian Pittman et al. 1 citation
Abstract Objective The goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the prevention of migraine and to consider the blinding integrity of an active control agent. Background The administration of a single low dose of psilocybin was observed to have lasting therapeutic effects in one small pilot trial in migraine, although the...
Neurology April 7, 2025 Emmanuelle A. D. Schindler, Christopher Gottschalk, Deepak Cyril D’souza 2 citations
To examine the relationship of acute psychedelic effects and measures of mental health with headache frequency in clinical trials of psilocybin in migraine and cluster headache.
The International Journal of Neuropsychopharmacology April 1, 2025 Jacob S. Aday, Otto Simonsson, Emmanuelle A. D. Schindler et al. 25 citations
Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic...
CNS Drugs September 1, 2024 Emmanuelle A. D. Schindler 2 citations
Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grown. The use and reported therapeutic effects of such treatments have long been reported, though formal clinical trials are only recently taking place. When considering how these substances might be further studied and eventually applied, it is...
Journal of the Neurological Sciences May 15, 2024 Emmanuelle A. D. Schindler, R Andrew Sewell, Christopher Gottschalk et al. 37 citations
In a recent randomized, double-blind, placebo-controlled study, we observed a nonsignificant reduction of attack frequency in cluster headache after pulse administration of psilocybin (10 mg/70 kg, 3 doses, 5 days apart each). We carried out a blinded extension phase to consider the safety and efficacy of repeating the pulse regimen. Eligible participants returned to receive a psilocybin pulse...
Journal of Military, Veteran and Family Health December 1, 2023 Emmanuelle A. D. Schindler, Jason J. Sico
LAY SUMMARY Patients with headache disorders, such as migraine or cluster headache, often have poor quality of life and can be disabled by their condition. Military members and Veterans have a high risk of developing a headache disorder, particularly because they are also at risk for brain injury through head trauma. New headache treatments are needed, because the available treatments may not...
Current Pain and Headache Reports September 1, 2023 Emmanuelle A. D. Schindler 7 citations
This review presents the existing literature of and a framework for how psychedelic drugs might be applied as therapeutic agents in episodic migraine. The therapeutic effects of psychedelics in headache disorders have been reported for decades and controlled investigations are now beginning. In the first and only clinical trial of a psychedelic drug in migraine, the single administration of...
Frontiers in Neurology June 29, 2023 Benjamin N. Blond, Emmanuelle A. D. Schindler 11 citations
Classic psychedelics are currently re-emerging as therapeutic agents with unique clinical benefits; however, it is also important to recognize the adverse effects of this drug class. While the risk of seizures with this drug class is known, the literature is lacking in detail. We present a case of psychedelic mushroom-induced seizures in a person with refractory right temporal lobe epilepsy...
Expert Review of Neurotherapeutics 2023 Emmanuelle A. D. Schindler, Peter S. Hendricks 5 citations
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes...
Headache: The Journal of Head and Face Pain November 1, 2022 Christina Luddy, Yutong Zhu, Hayley Lindsey et al. 75 citations
Abstract Objective Using a patient‐informed regimen, we conducted an exploratory randomized, double‐blind, placebo‐controlled study to systematically investigate the effects of psilocybin in cluster headache. Background Sustained reductions in cluster headache burden after limited quantities of psilocybin‐containing mushrooms are anecdotally reported, although to date there are no controlled...
Current Pain and Headache Reports June 27, 2022 Sakari Santeri Rusanen, Suchetana De, Emmanuelle A. D. Schindler et al. 12 citations
Abstract Purpose of Review The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surveys. The aim of the study is to systematically review published survey studies to evaluate the reported efficacies of both established and unconventional substances in abortive and prophylactic treatment of both episodic and chronic CH, specifically...
Neuropharmacology June 16, 2022 Emmanuelle A. D. Schindler 29 citations
The effects of psychedelic drugs in headache and chronic pain disorders have been reported for several decades, and now controlled studies are emerging. The existing evidence supports a lasting therapeutic benefit after limited dosing, a unique feature of the drug class that distinguishes it from conventional treatment. This commentary summarizes these reports of preventive effects of...
Current Topics in Behavioral Neurosciences 2022 Emmanuelle A. D. Schindler
The therapeutic potential of psychedelics in headache and chronic pain disorders is documented over decades of anecdotal and early investigational reports, which have paved the way for the first controlled studies of psilocybin and lysergic acid diethylamide (LSD) in these disorders. The reported lasting clinical effects after limited dosing with psychedelics present a novel means for disease...
Neurotherapeutics 2021 Emmanuelle A. D. Schindler, R Andrew Sewell, Christopher Gottschalk et al. 138 citations
While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test...
Frontiers in Pharmacology March 1, 2018 Emmanuelle A. D. Schindler, Ryan M Wallace, Jordan Sloshower et al.
Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric...
Journal of Psychoactive Drugs October 20, 2015 Emmanuelle A. D. Schindler, Christopher Gottschalk, Marsha J. Weil et al. 104 citations
Cluster headache is one of the most debilitating pain syndromes. A significant number of patients are refractory to conventional therapies. The Clusterbusters.org medication use survey sought to characterize the effects of both conventional and alternative medications used in cluster headache. Participants were recruited from cluster headache websites and headache clinics. The final analysis...
Brain Research November 1, 2012 Emmanuelle A. D. Schindler, John A. Harvey, Vincent J. Aloyo
The phenethylamine and indoleamine classes of hallucinogens demonstrate distinct pharmacological properties, although they share a serotonin(2A) (5-HT(2A)) receptor mechanism of action (MOA). The 5-HT(2A) receptor signals through phosphatidylinositol (PI) hydrolysis, which is initiated upon activation of phospholipase C (PLC). The role of PI hydrolysis in the effects of hallucinogens remains...
Pharmacology, Biochemistry, and Behavior December 15, 2011 Emmanuelle A. D. Schindler, Kuldip D. Dave, Elaine M. Smolock et al. 18 citations
RationaleAfter decades of social stigma, hallucinogens have reappeared in the clinical literature demonstrating unique benefits in medicine. The precise behavioral pharmacology of these compounds remains unclear, however.ObjectivesTwo commonly studied hallucinogens, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD), were investigated both in vivo and...
Psychopharmacology October 1, 2010 Anthony G Romano, Jennifer L Quinn, Luchuan Li et al. 42 citations
Parenteral injections of d-lysergic acid diethylamide (LSD), a serotonin 5-HT(2A) receptor agonist, enhance eyeblink conditioning. Another hallucinogen, (±)-1(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), was shown to elicit a 5-HT(2A)-mediated behavior (head bobs) after injection into the hippocampus, a structure known to mediate trace eyeblink conditioning. This study aims...